arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HALOZYME THERAPEUTICS, INC.

HALO
$112.46 ▼ -2.65 (-2.30%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

HALOZYME THERAPEUTICS, INC. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $13.2B
Dividend Yield —
Revenue Growth 47.7% ↗
Op. Margin 59.8% ↗
ROIC 11.2% ↗
FCF / Share $2.02 ↗
Trailing P/E 57.4x
Price / Book 89.4x
FCF Yield 1.8%
Debt / Equity 13.50
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$481.00M
↑ +47.7% —
Net Income Profit after all expenses
$229.91M
↑ +39.2% —
Operating Margin Operating profit as % of sales
59.8%
↑ +22.1% 89th
FCF / Share Free cash flow per share
$2.02
↑ +35.2% —
Long-Term Debt Long-term obligations
$1.94B
— +0.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
90
Financial Health ↑
47
Cash Quality ↑
86

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters